Oncternal Therapeutics Dirección
Dirección controles de criterios 3/4
El CEO de Oncternal Therapeutics es Jim Breitmeyer , nombrado en Jun 2019, tiene una permanencia de 5.42 años. compensación anual total es $1.62M, compuesta por 37.5% salario y 62.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.11% de las acciones de la empresa, por valor de $38.03K. La antigüedad media del equipo directivo y de la junta directiva es de 3.8 años y 5.4 años, respectivamente.
Información clave
Jim Breitmeyer
Chief Executive Officer (CEO)
US$1.6m
Compensación total
| Porcentaje del salario del CEO | 37.5% |
| Permanencia del CEO | 5.4yrs |
| Participación del CEO | 1.1% |
| Permanencia media de la dirección | 3.8yrs |
| Promedio de permanencia en la Junta Directiva | 5.4yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think Some Shareholders May Hesitate To Increase Oncternal Therapeutics, Inc.'s (NASDAQ:ONCT) CEO Compensation
Jun 14
Can Oncternal Therapeutics (NASDAQ:ONCT) Afford To Invest In Growth?
Mar 03Here's Why We're A Bit Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Nov 06Oncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wisely
Jul 12We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Jan 12FDA clears Oncternal to proceed with dose escalation study for lymphoma car-T therapy
Oct 03Oncternal Therapeutics begins phase 3 study of zilovertamab
Sep 27Oncternal Therapeutics: Selling For Under Cash Value
Sep 02Oncternal Therapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $0.2M misses by $0.26M
Aug 09Here's Why We're Watching Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Situation
Aug 07Oncternal to collaborate with an AbbVie company for its phase 3 lymphoma study
Jul 14Oncternal Therapeutics: As Phase 2 Study Matures, Data Continues To Improve
Jun 07We're Keeping An Eye On Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn Rate
Apr 12Oncternal Therapeutics: Trading Near Cash With Impressive Results
Jan 04Oncternal Therapeutics (NASDAQ:ONCT) Is In A Good Position To Deliver On Growth Plans
Nov 09Oncternal Therapeutics: Keep An Eye On This Biopharmaceutical Company
Oct 10Oncternal: Solid Data In 2 Cancers With High Unmet Need
Jun 17We Think Oncternal Therapeutics (NASDAQ:ONCT) Can Afford To Drive Business Growth
May 05Should Oncternal Therapeutics (NASDAQ:ONCT) Be Disappointed With Their 81% Profit?
Mar 01Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$35m |
| Jun 30 2024 | n/a | n/a | -US$36m |
| Mar 31 2024 | n/a | n/a | -US$36m |
| Dec 31 2023 | US$2m | US$609k | -US$39m |
| Sep 30 2023 | n/a | n/a | -US$42m |
| Jun 30 2023 | n/a | n/a | -US$43m |
| Mar 31 2023 | n/a | n/a | -US$46m |
| Dec 31 2022 | US$2m | US$580k | -US$44m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$39m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | US$5m | US$557k | -US$31m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | n/a | n/a | -US$21m |
| Mar 31 2021 | n/a | n/a | -US$18m |
| Dec 31 2020 | US$780k | US$530k | -US$17m |
| Sep 30 2020 | n/a | n/a | -US$19m |
| Jun 30 2020 | n/a | n/a | -US$19m |
| Mar 31 2020 | n/a | n/a | -US$37m |
| Dec 31 2019 | US$1m | US$502k | -US$34m |
| Sep 30 2019 | n/a | n/a | -US$31m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$7m |
| Dec 31 2018 | US$518k | US$426k | -US$7m |
Compensación vs. Mercado: La compensación total de Jim($USD1.62M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD650.80K).
Compensación vs. Ingresos: La compensación de Jim ha sido consistente con los resultados de la empresa en el último año.
CEO
Jim Breitmeyer (70 yo)
5.4yrs
Permanencia
US$1,623,074
Compensación
Dr. James B. Breitmeyer, also known as Jim, M.D., Ph D., served as Director of Otonomy, Inc. since June 20, 2018 until February 2023. He serves as Director of Rebalance Health, Inc. He serves as the Chief...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 5.4yrs | US$1.62m | 1.11% $ 38.0k | |
| CFO & Treasurer | 5.4yrs | US$847.91k | 0.25% $ 8.5k | |
| Chief Technical & Scientific Officer | 3.8yrs | sin datos | 0.074% $ 2.6k | |
| General Counsel & Secretary | 3.6yrs | sin datos | 0.14% $ 4.9k | |
| Senior Vice President of Corporate Development | 3.3yrs | sin datos | sin datos |
3.8yrs
Permanencia media
55.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de ONCT se considera experimentado (3.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 5.4yrs | US$1.62m | 1.11% $ 38.0k | |
| Independent Director | 18.5yrs | US$59.80k | 0.12% $ 4.2k | |
| Independent Director | 5.4yrs | US$67.50k | 0.017% $ 579.9 | |
| Independent Director | 5.4yrs | US$67.00k | 0.044% $ 1.5k | |
| Independent Chairman of the Board | 5.4yrs | US$103.82k | 0.024% $ 828.1 | |
| Independent Director | 3.8yrs | US$61.32k | 0.00017% $ 5.8 | |
| Scientific Advisor | no data | sin datos | sin datos | |
| Independent Director | 5.4yrs | US$59.00k | 0.025% $ 850.4 | |
| Non-Independent Director | 5.4yrs | US$55.00k | 0.34% $ 11.6k | |
| Cell Therapy Scientific Advisory Board Member | 3yrs | sin datos | sin datos | |
| Prostate Cancer & Cell Therapy Scientific Advisory Board Member | 1.8yrs | US$941.21k | 0.062% $ 2.1k | |
| Cell Therapy Scientific Advisory Board Member | 3yrs | sin datos | sin datos |
5.4yrs
Permanencia media
70yo
Promedio de edad
Junta con experiencia: La junta directiva de ONCT se considera experimentada (5.4 años de antigüedad promedio).